Janux Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 144.95K shares, a 295.50% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 360.72K shares, a 247.23% increase year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 218.26K shares, a 59.51% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 42.31K shares, a 75.36% decline year-over-year.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 401.11K shares, a 65.19% decline from fiscal 2024.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.15M shares, a 354.43% increase from fiscal 2023.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 253.54K shares, a 3323.97% increase from fiscal 2022.
- Janux Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 7.41K shares, a 98.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 144.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 766.24K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 360.72K shares 10-Q · filed 2026-05-07 | 657.95K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 218.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 401.11K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 42.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 721.91K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | 36.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 851.36K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | 103.88K shares 10-Q · filed 2025-05-08 | 1.07M shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | 539.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.15M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 171.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 674.80K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | 255.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 546.26K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | 186.28K shares 10-Q · filed 2024-05-08 | 291.18K shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | 61.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 253.54K shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 43.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 191.88K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 148.65K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 148.65K shares 10-Q · filed 2023-05-09 | 149.65K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | 7.41K shares 10-K · filed 2023-03-10 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 7.41K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 1.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 7.41K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 6.41K shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 635.32K shares 10-K · filed 2022-03-18 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |